With regard to our manuscripts on the commercial saliva substitute, Oralbalance®—its formula has been changed – Online First – Springer

To the editor,

Previously, we published two articles in Supportive Care in Cancer on the in vitro and in vivo antibacterial effects of a commercial saliva substitute, Oralbalance® (Laclede, Inc., Rancho Dominguez, CA, USA; now GlaxoSmithKline, UK), which was a historic product for over 20 years and contributed to oral management for cancer patients with side effects such as xerostomia.

via With regard to our manuscripts on the commercial saliva substitute, Oralbalance®—its formula has been changed – Online First – Springer.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s